blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2111863

EP2111863 - Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.02.2013
Database last updated on 24.04.2024
Most recent event   Tooltip18.07.2014Lapse of the patent in a contracting state
New state(s): HU		published on 20.08.2014  [2014/34]
Applicant(s)For all designated states
Asahi Kasei Pharma Corporation
1-105 Kanda Jinbocho Chiyoda-ku
Tokyo 101-8101 / JP
[2009/44]
Inventor(s)01 / Fong, Benson
2000 Sierra Point Parkway
Suite 600
Brisbane, California 94005-1846 / US
 [2012/13]
Former [2009/44]01 / Fong, Benson
2000 Sierra Point Parkway Suite 600
Brisbane, California 94005-1846 / US
Representative(s)Forstmeyer, Dietmar, et al
Boeters & Lieck
Oberanger 32
80331 München / DE
[N/P]
Former [2009/44]Forstmeyer, Dietmar, et al
BOETERS & LIECK Oberanger 32
80331 München / DE
Application number, filing date09007232.325.10.2006
[2009/44]
Priority number, dateUS20050730273P26.10.2005         Original published format: US 730273 P
[2009/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2111863
Date:28.10.2009
Language:EN
[2009/44]
Type: B1 Patent specification 
No.:EP2111863
Date:28.03.2012
Language:EN
[2012/13]
Search report(s)(Supplementary) European search report - dispatched on:EP02.09.2009
ClassificationIPC:A61K31/551, A61K31/506, A61P9/10, A61P9/12
[2009/44]
CPC:
A61K31/192 (EP,US); A61K31/137 (EP,US); A61K31/22 (EP,US);
A61K31/343 (EP,US); A61K31/353 (EP,US); A61K31/366 (EP,US);
A61K31/401 (EP,US); A61K31/4409 (EP,US); A61K31/455 (EP,US);
A61K31/506 (EP,US); A61K31/519 (EP,US); A61K31/551 (EP,US);
A61K31/554 (EP,US); A61K31/5578 (EP,US); A61K45/06 (EP,US);
A61P11/00 (EP); A61P43/00 (EP); A61P9/08 (EP);
A61P9/10 (EP); A61P9/12 (EP) (-)
C-Set:
A61K31/137, A61K2300/00 (US,EP);
A61K31/192, A61K2300/00 (US,EP);
A61K31/22, A61K2300/00 (US,EP);
A61K31/343, A61K2300/00 (US,EP);
A61K31/353, A61K2300/00 (EP,US);
A61K31/366, A61K2300/00 (EP,US);
A61K31/401, A61K2300/00 (EP,US);
A61K31/4409, A61K2300/00 (US,EP);
A61K31/455, A61K2300/00 (US,EP);
A61K31/506, A61K2300/00 (US,EP);
A61K31/519, A61K2300/00 (US,EP);
A61K31/551, A61K2300/00 (US,EP);
A61K31/554, A61K2300/00 (US,EP);
A61K31/5578, A61K2300/00 (US,EP)
(-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/44]
TitleGerman:Fasudil in Kombination mit Bosentan zur Behandlung von pulmonaler arterieller Hypertonie[2009/44]
English:Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension[2009/44]
French:Combinaison du fasudil et bosentan pour le traitement de l'hypertension artérielle pulmonaire[2009/44]
Examination procedure02.12.2009Examination requested  [2010/02]
05.01.2010Despatch of a communication from the examining division (Time limit: M06)
04.06.2010Reply to a communication from the examining division
08.07.2011Communication of intention to grant the patent
10.10.2011Fee for grant paid
10.10.2011Fee for publishing/printing paid
Parent application(s)   TooltipEP06826765.7  / EP1951253
Divisional application(s)EP11000632.7  / EP2351569
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060826765) is  30.01.2009
Opposition(s)03.01.2013No opposition filed within time limit [2013/10]
Fees paidRenewal fee
24.07.2009Renewal fee patent year 03
24.07.2009Renewal fee patent year 04
20.10.2010Renewal fee patent year 05
19.10.2011Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU25.10.2006
AT28.03.2012
BE28.03.2012
CY28.03.2012
CZ28.03.2012
DK28.03.2012
EE28.03.2012
FI28.03.2012
IT28.03.2012
LT28.03.2012
LV28.03.2012
NL28.03.2012
PL28.03.2012
RO28.03.2012
SE28.03.2012
SI28.03.2012
SK28.03.2012
TR28.03.2012
BG28.06.2012
GR29.06.2012
ES09.07.2012
IS28.07.2012
PT30.07.2012
IE25.10.2012
LU25.10.2012
CH31.10.2012
LI31.10.2012
MC31.10.2012
[2014/34]
Former [2014/27]AT28.03.2012
BE28.03.2012
CY28.03.2012
CZ28.03.2012
DK28.03.2012
EE28.03.2012
FI28.03.2012
IT28.03.2012
LT28.03.2012
LV28.03.2012
NL28.03.2012
PL28.03.2012
RO28.03.2012
SE28.03.2012
SI28.03.2012
SK28.03.2012
TR28.03.2012
BG28.06.2012
GR29.06.2012
ES09.07.2012
IS28.07.2012
PT30.07.2012
IE25.10.2012
LU25.10.2012
CH31.10.2012
LI31.10.2012
MC31.10.2012
Former [2014/21]AT28.03.2012
BE28.03.2012
CY28.03.2012
CZ28.03.2012
DK28.03.2012
EE28.03.2012
FI28.03.2012
IT28.03.2012
LT28.03.2012
LV28.03.2012
NL28.03.2012
PL28.03.2012
RO28.03.2012
SE28.03.2012
SI28.03.2012
SK28.03.2012
TR28.03.2012
BG28.06.2012
GR29.06.2012
ES09.07.2012
IS28.07.2012
PT30.07.2012
IE25.10.2012
CH31.10.2012
LI31.10.2012
MC31.10.2012
Former [2013/33]AT28.03.2012
BE28.03.2012
CY28.03.2012
CZ28.03.2012
DK28.03.2012
EE28.03.2012
FI28.03.2012
IT28.03.2012
LT28.03.2012
LV28.03.2012
NL28.03.2012
PL28.03.2012
RO28.03.2012
SE28.03.2012
SI28.03.2012
SK28.03.2012
BG28.06.2012
GR29.06.2012
ES09.07.2012
IS28.07.2012
PT30.07.2012
IE25.10.2012
CH31.10.2012
LI31.10.2012
MC31.10.2012
Former [2013/24]AT28.03.2012
BE28.03.2012
CY28.03.2012
CZ28.03.2012
DK28.03.2012
EE28.03.2012
FI28.03.2012
IT28.03.2012
LT28.03.2012
LV28.03.2012
NL28.03.2012
PL28.03.2012
RO28.03.2012
SE28.03.2012
SI28.03.2012
SK28.03.2012
GR29.06.2012
ES09.07.2012
IS28.07.2012
PT30.07.2012
MC31.10.2012
Former [2013/22]AT28.03.2012
BE28.03.2012
CY28.03.2012
CZ28.03.2012
DK28.03.2012
EE28.03.2012
FI28.03.2012
IT28.03.2012
LT28.03.2012
LV28.03.2012
NL28.03.2012
PL28.03.2012
RO28.03.2012
SE28.03.2012
SI28.03.2012
SK28.03.2012
GR29.06.2012
ES09.07.2012
IS28.07.2012
PT30.07.2012
Former [2013/11]AT28.03.2012
BE28.03.2012
CY28.03.2012
CZ28.03.2012
DK28.03.2012
EE28.03.2012
FI28.03.2012
IT28.03.2012
LT28.03.2012
LV28.03.2012
NL28.03.2012
PL28.03.2012
RO28.03.2012
SE28.03.2012
SI28.03.2012
SK28.03.2012
GR29.06.2012
IS28.07.2012
PT30.07.2012
Former [2013/08]AT28.03.2012
BE28.03.2012
CY28.03.2012
CZ28.03.2012
DK28.03.2012
EE28.03.2012
FI28.03.2012
LT28.03.2012
LV28.03.2012
NL28.03.2012
PL28.03.2012
RO28.03.2012
SE28.03.2012
SI28.03.2012
SK28.03.2012
GR29.06.2012
IS28.07.2012
PT30.07.2012
Former [2013/07]AT28.03.2012
BE28.03.2012
CY28.03.2012
CZ28.03.2012
EE28.03.2012
FI28.03.2012
LT28.03.2012
LV28.03.2012
PL28.03.2012
RO28.03.2012
SE28.03.2012
SI28.03.2012
SK28.03.2012
GR29.06.2012
IS28.07.2012
PT30.07.2012
Former [2013/01]BE28.03.2012
CY28.03.2012
CZ28.03.2012
EE28.03.2012
FI28.03.2012
LT28.03.2012
LV28.03.2012
PL28.03.2012
RO28.03.2012
SE28.03.2012
SI28.03.2012
SK28.03.2012
GR29.06.2012
IS28.07.2012
PT30.07.2012
Former [2012/50]BE28.03.2012
CY28.03.2012
CZ28.03.2012
EE28.03.2012
FI28.03.2012
LT28.03.2012
LV28.03.2012
PL28.03.2012
RO28.03.2012
SE28.03.2012
SI28.03.2012
SK28.03.2012
GR29.06.2012
IS28.07.2012
Former [2012/49]BE28.03.2012
CY28.03.2012
CZ28.03.2012
EE28.03.2012
FI28.03.2012
LT28.03.2012
LV28.03.2012
PL28.03.2012
RO28.03.2012
SE28.03.2012
SI28.03.2012
GR29.06.2012
IS28.07.2012
Former [2012/48]BE28.03.2012
CY28.03.2012
EE28.03.2012
FI28.03.2012
LT28.03.2012
LV28.03.2012
SE28.03.2012
GR29.06.2012
Former [2012/46]BE28.03.2012
CY28.03.2012
FI28.03.2012
LT28.03.2012
LV28.03.2012
GR29.06.2012
Former [2012/41]CY28.03.2012
FI28.03.2012
LT28.03.2012
LV28.03.2012
GR29.06.2012
Former [2012/39]FI28.03.2012
LT28.03.2012
LV28.03.2012
GR29.06.2012
Former [2012/37]FI28.03.2012
LT28.03.2012
GR29.06.2012
Former [2012/36]LT28.03.2012
GR29.06.2012
Former [2012/34]LT28.03.2012
Documents cited:Search[Y]  - NAGAOKA TETSUTARO ET AL, "Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 1 MAR 2005, (20050301), vol. 171, no. 5, ISSN 1073-449X, pages 494 - 499, XP002542152 [Y] 1-5 * figure 5 *

DOI:   http://dx.doi.org/10.1164/rccm.200405-637OC
 [Y]  - WEITZENBLUM E, "ACTUALITE SUR L'HYPERTENSION ARTERIELLE PULMONAIRE (HTAP) <>//UPDATE ON IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION", REVUE DES MALADIES RESPIRATOIRES, PARIS, FR, (20040101), vol. 21, no. 5II, ISSN 0761-8425, page 7S82/7S83, XP008041693 [Y] 1-5 * page 7S83, column R *
 [Y]  - DASHWOOD M R ET AL, "[3H]bosentan binding to human coronary artery: functional correlates.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 1995, (1995), vol. 26 Suppl 3, ISSN 0160-2446, pages S376 - S379, XP009121647 [Y] 1-5 * the whole document *
by applicantHU151865
 US2882271
 US3152173
 GB1025578
 US3261859
 US3262977
 US3267104
 US3371014
 US3485847
 US3562257
 US3773939
 US3799934
 US3962238
 US3985758
 US4154839
 US4220649
 US4264611
 US4338322
 EP0106275
 US4446325
 US4466972
 US4567175
 US4572909
 US4663325
 US4672068
 US4692464
 US4705797
 US4786635
 US4801599
 US4808605
 US4885284
 US4892875
 US4952592
 WO2012065758
    - D'ALONZO, G.E. ET AL., ANN INTERN MED, (1991), vol. 115, pages 343 - 349
    - PALEVSKY, H.I. ET AL., CIRCULATION, (1989), vol. 80, pages 1207 - 1221
    - RUBIN, L.J., N ENGL JMED, (1997), vol. 336, pages 111 - 117
    - WAGENVOORT, C.A.; WAGENVOORT, N., CIRCULATION, (1970), vol. 42, pages 1163 - 1184
    - WOOD, P., BR HEART J, (1958), vol. 20, pages 557 - 570
    - GIAID, A.; SALEH, D., N ENGL J MED, (1995), vol. 333, pages 214 - 221
    - XUE, C; JOHNS, R.A., N ENGL J MED, (1995), vol. 333, pages 1642 - 1644
    - ABE K.; 2004 ET AL., CIRC. RES., vol. 94, pages 385 - 393
    - FAGAN K.A. ET AL., AM. J. PHYSIOL. LUNG CELL. MOL. PHYSIOL., (2004), vol. 287, pages L656 - L664
    - NAGAOKA ET AL., AM. J. PHYSIOL. LUNG CELL MOL. PHYSIOL., (2004), vol. 287, pages L665 - L672
    - NAGAOKA ET AL., AM. J. RESPIR. CRIT. CARE MED., (2005), vol. 171, pages 494 - 499
    - VAN AELST; D'SOUZA-SCHOREY, GENES DEV., (1997), vol. 11, pages 2295 - 2322
    - SAUZEAU ET AL., J. BIOL. CHEM., (2000), vol. 275, pages 21722 - 21729
    - GUDI ET AL., J. BIOL. CHEM., (2002), vol. 277, pages 37382 - 37393
    - ROBERTSON ET AL., BR. J. PHARMACOL., (2000), vol. 131, pages 5 - 9
    - WANG ET AL., AM. J. RESPIR. CELL MOL. BIOL., (2001), vol. 25, pages 628 - 635
    - WILSON ET AL., J CELL BIOL., (1993), vol. 123, pages 741 - 747
    - LIU ET AL., CIRC. RES., (2004), vol. 95, pages 579 - 586
    - TAKEMOTO ET AL., CIRCULATION, (2002), vol. 106, pages 57 - 62
    - FAGAN L.A.; 2004 ET AL., AM. J PHYSIOL. LUNG CELL MOL. PHYSIOL., vol. 287, pages L656 - L664
    - NAGAOKA; 2004 ET AL., AM. J. PHYSIOL. LUNG CELL MOL. PHYSIOL., vol. 287, pages L665 - L672
    - UEHATA ET AL., NATURE, (1997), vol. 389, pages 990 - 994
    - NAGAOKA; 2005 ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 171, pages 494 - 499
    - SHIMOKAWA H. ET AL., CARDIOVASC. RES., (1999), vol. 43, pages 1029 - 1039
    - FUKUMOTO Y. ET AL., HEART, (2005), vol. 91, pages 391 - 392
    - SASAKI ET AL., PHARMACOL THER., (2002), vol. 93, pages 225 - 32
    - SHIMOKAWA; TAKESHITA, THROMB VASE BIOL, (2005), vol. 25, pages X - X
    - HIROOKA; SHIMOKAWA, AM J CARDIOVASC DRUGS, (2005), vol. 5, no. 1, pages 31 - 39
    - TRAMONTANO ET AL., BIOCHEM BIOPHYS RES COMM, (2004), vol. 320, pages 34 - 38
    - OHNAKA ET AL., BIOCHEM BIOPHYS RES COMM, (2001), vol. 287, pages 337 - 342
    - BARST R.J. ET AL., NENGL JMED, (1996), vol. 334, pages 296 - 301
    - BADESCH D.B. ET AL., ANN INTERN MED, (2000), vol. 132, pages 425 - 434
    - WALMRATH D. ET AL., LANCET, (1993), vol. 342, pages 961 - 962
    - WALMRATH D. ET AL., AM JRESPIR CRIT CARE MED, (1995), vol. 151, pages 724 - 730
    - WALMRATH D. ET AL., AM J RESPIR CRIT CARE MED, (1996), vol. 153, pages 991 - 996
    - ZWISSLER B. ET AL., AM J RESPIR CRIT CARE MED, (1996), vol. 154, pages 1671 - 1677
    - OLSCHEWSKI H. ET AL., AM JRESPIR CRIT CARE MED, (1999), vol. 160, pages 600 - 607
    - BARST, R.J., J. AM. COLL. CARDIOL., (2003), vol. 41, pages 2119 - 25
    - ABE K. ET AL., J CARDIOVASC PHARMACOL, (2005), vol. 45, pages 120 - 124
    - FITSCHA P. ET AL., ADV PROSTAGLANDIN THRONZBOXANE LEUKOT RES, (1987), vol. 17, pages 450 - 454
    - HOEPER M.M. ET AL., JAM COLL CARDIOL, (2000), vol. 35, pages 176 - 182
    - OLSCHEWSKI H. ET AL., AM J RESPIR CRIT CARE MED, (1999), vol. 160, pages 600 - 607
    - OLSCHEWSKI H. ET AL., ANN INTERN MED, (1996), vol. 124, pages 820 - 824
    - GESSLER T. ET AL., EUR RESPIR J, (2001), vol. 17, pages 14 - 19
    - WENSEL R. ET AL., CIRCULATION, (2000), vol. 101, pages 2388 - 2392
    - HOEPER M.M. ET AL., N ENGL JMED, (2000), vol. 342, pages 1866 - 1870
    - OLSCHEWSKI H. ET AL., INTENSIVE CARE MED, (1998), vol. 24, pages 631 - 634
    - STRICKER H. ET AL., SCHWEIZ MED WOCHENSCHR, (1999), vol. 129, pages 923 - 927
    - OLSCHEWSKI H. ET AL., ANN INTERN MED, (2000), vol. 132, pages 435 - 443
    - BEGHETTI M. ET AL., HEART, (2001), vol. 86, pages E10 - E10
    - OLSCHEWSKI H ET AL., NEJM, (2002), vol. 345, pages 322 - 9
    - DOGGRELL S.A., EXPERT OPIN. INVESTIG. DRUGS, (2004), vol. 13, pages 7865 - 874
    - MYATA M. ET AL., LUNG, (2000), vol. 178, pages 63 - 73
    - MYATA M. ET AL., LUNG, vol. 178, pages 63 - 73
    - HIRONAKA E. ET AL., CARDIOVASC. RES., (2003), vol. 60, pages 692 - 629
    - MYATA M. ET AL., CHEST, (2001), vol. 119, pages 554 - 561
    - SAINI H.K. ET AL., CAARDIOVASC. DRUG REV., (2004), vol. 22, pages 27 - 54
    - SETOGUCHI Y. ET AL., PHARMACOL, (2002), vol. 64, pages 71 - 75
    - KATO S. ET AL., RESPIROLOGY, (2000), vol. 5, pages 27 - 32
    - KATO S. ET AL., J.INT. MED. RES., (2000), vol. 28, pages 258 - 268
    - KINUGAWA ET AL., AM HEART J, (2002), vol. 144
    - CHANNICK RN. ET AL., LANCET, (2001), vol. 358, pages 1119 - 1123
    - RUBIN L.J. ET AL., N ENGL J MED, (2002), vol. 346, pages 896 - 903
    - NAGAYA N. ET AL., AM JRESPIR CRIT CARE MED, (2001), vol. 163, pages 887 - 891
    - MICHELAKIS E. ET AL., CIRCULATION, (2002), vol. 105, pages 2398 - 2403
    - GHOFRANI H. ET AL., LANCET, (2002), vol. 360, pages 895 - 900
    - SCHERMULY R..T., J PHANNACOL EXP THER, (2000), vol. 292, pages 512 - 20
    - GHOFRANI ET AL., CRIT CARE MED, (2002), vol. 30, pages 2489 - 92
    - GHOFRANI ET AL., JAM COLL CARDIOL, (2003), vol. 42, pages 158 - 164
    - GHOFRANI ET AL., ANN INTERN MED, (2002), vol. 136, pages 515 - 22
    - OKA M., AM J PHYSIOL LUNG CELL MOL PHYSIOL, (2001), vol. 280, pages L432 - L435
    - MORIO Y.; MCMURTRY I.F., JAPPL PHYSIOL, (2002), vol. 92, pages 527 - 534
    - KATO ET AL., RESPIROLOGY, (2000), vol. 5, pages 27 - 32
    - KATO ET AL., J INT. MED. RES., (2000), vol. 28, pages 258 - 268
    - DOGGRELL, EXPERT OPIN. INVESTIG. DRUGS, (2004), vol. 13, pages 7865 - 874
    - SAINI ET AL., CARDIOVASC. DRUG REV., (2004), vol. 22, pages 27 - 54
    - ABE ET AL., J CARDIOVASC PHARMACOL, (2005), vol. 45, pages 120 - 124
    - NAGAOKA ET AL., AM. J. PHYSIOL LUNG CELL MOL. PHYSIOL., (2004), vol. 287, pages L665 - L672
    - FUKUMOTO ET AL., HEART, (2005), vol. 91, pages 391 - 392
    - ABE ET AL., CIRC RES, (2004), vol. 94, pages 385 - 393
    - SHIMOKAWA ET AL., CARDIOVASC. RES., (2005), vol. 43, pages 1029 - 1039
    - HIROOKA ET AL., AM J CARDIOVASC DRUGS, (2005), vol. 5, no. 1, pages 31 - 39
 US20050730273
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.